Biohaven Advances a New Class of Precision Immunology Therapies: First MoDE Extracellular Protein Degrader, BHV-1300, Begins Phase 3 Pivotal Trial in Graves' Disease
Biohaven enrolled the first patient in a pivotal Phase 3 trial of BHV-1300, the first MoDE extracellular protein degrader to reach this stage, for the treatment of Graves' disease. The therapy targets the TSHR-IgG1 autoantibody driving the disease rather than the thyroid gland itself, addressing a significant unmet need as no new FDA-approved therapies have emerged in over 70 years.
Key figures
- Drug Name
- BHV-1300
- Phase Of Trial
- Phase 3
- Dosing regimen
- 1,000 mg SC weekly
- Global prevalence
- ~1%
- Primary endpoint weeks
- 26
- Trial enrollment target
- approximately 300 adults
- Phase 1b antibody reduction
- >80%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.